Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.43 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 3/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | KDM6B | O15054 | 1/20 | 0.38 |
| ▸ | TET3 | O43151 | 1/20 | 0.38 |
| ▸ | KDM4A | O75164 | 1/20 | 0.38 |
| ▸ | KDM4B | O94953 | 1/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.38 |
| ▸ | KDM5C | P41229 | 1/20 | 0.38 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.38 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10853180 | 0.85 | NPC1 (0.41) | AGTR1NPC1RAB9ANCOA1NCOA3 | |
| SCHEMBL10853187 | 0.85 | NPC1 (0.41) | AGTR1NPC1RAB9ANCOA1NCOA3 | |
| SCHEMBL10072495 | 0.80 | AGTR1 (0.37) | AGTR1ESR1ESR2KDM4ESMN1; SMN2 | |
| SCHEMBL2653303 | 0.79 | KMT2A (0.40) | AGTR1RAB9AESR1ESR2KDM4E | |
| SCHEMBL30949998 | 0.78 | ESR1 (0.36) | AGTR1NPC1RAB9ANCOA1NCOA3 | |
| SCHEMBL15881435 | 0.76 | KMT2A (0.35) | AGTR1ESR1ESR2KDM4ESMN1; SMN2 | |
| SCHEMBL30949901 | 0.75 | MAPT (0.37) | AGTR1KDM4ESMN1; SMN2ALDH1A1NPSR1 | |
| SCHEMBL30949909 | 0.75 | MAPT (0.37) | AGTR1KDM4ESMN1; SMN2ALDH1A1NPSR1 | |
| SCHEMBL29142169 | 0.75 | TRIM24 (0.43) | AGTR1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL29791320 | 0.75 | PLAU (0.37) | AGTR1ESR1ESR2ALDH1A1PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4617269-A1 | NOVEL COMPOUND AS RON INHIBITOR | LG CHEM, LTD. (KR) | 2025-09-17 | — | — | EP | disclosed |
| US-20240425480-A1 | NOVEL PYRIDINE DERIVATIVE COMPOUND AS RON INHIBITOR | LG CHEM, LTD. (KR) | 2024-12-26 | — | — | US | disclosed |
| US-20240316017-A1 | NOVEL PYRIDINE DERIVATIVE COMPOUND AS RON INHIBITOR | LG CHEM, LTD. (KR) | 2024-09-26 | — | — | US | disclosed |
| US-20240293386-A1 | NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR | LG CHEM, LTD. (KR) | 2024-09-05 | — | — | US | disclosed |
| WO-2024134517-A1 | NOVEL COMPOUND AS RON INHIBITOR | 주식회사 엘지화학 | 2024-06-27 | — | — | WO | disclosed |
| EP-4349826-A1 | NOVEL PYRIDINE DERIVATIVE COMPOUND AS RON INHIBITOR | LG Chem, Ltd. (KR) | 2024-04-10 | — | — | EP | disclosed |
| EP-4349825-A1 | NOVEL PYRIDINE DERIVATIVE COMPOUND AS RON INHIBITOR | LG Chem, Ltd. (KR) | 2024-04-10 | — | — | EP | disclosed |
| EP-4332106-A1 | NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR | LG Chem, Ltd. (KR) | 2024-03-06 | — | — | EP | disclosed |
| WO-2022270976-A1 | NOVEL PYRIDINE DERIVATIVE COMPOUND AS RON INHIBITOR | 주식회사 엘지화학 | 2022-12-29 | — | — | WO | disclosed |
| WO-2022270977-A1 | NOVEL PYRIDINE DERIVATIVE COMPOUND AS RON INHIBITOR | 주식회사 엘지화학 | 2022-12-29 | — | — | WO | disclosed |
| US-8124768-B2 | 4-pyridinone compounds and their use for cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-28 | — | — | US | disclosed |
| US-20110034416-A1 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER | BRISTOL-MYERS SQUIBB COMPANY | 2011-02-10 | — | — | US | disclosed |
| US-20110034416-A1 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER | BRISTOL-MYERS SQUIBB COMPANY | 2011-02-10 | — | — | US | disclosed |
| US-20110034416-A1 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER | BRISTOL-MYERS SQUIBB COMPANY | 2011-02-10 | — | — | US | disclosed |
| EP-2235001-A1 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER | Bristol-Myers Squibb Company (US) | 2010-10-06 | — | — | EP | disclosed |
| EP-2235002-A1 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER | Bristol-Myers Squibb Company (US) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009094427-A1 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009094427-A1 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009094417-A1 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009094417-A1 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034416-A1 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER | DPYD, CDK4, G6PD | AGTR1 1504/4885NPC1 1626/4885RAB9A 1324/4885 |
| US-20240425480-A1 | NOVEL PYRIDINE DERIVATIVE COMPOUND AS RON INHIBITOR | RET, MST1R, ROS1 | AGTR1 1618/4885NPC1 1674/4885RAB9A 996/4885 |
| US-20240316017-A1 | NOVEL PYRIDINE DERIVATIVE COMPOUND AS RON INHIBITOR | RET, ROS1, MST1R | AGTR1 1478/4885NPC1 1429/4885RAB9A 875/4885 |
| US-20240293386-A1 | NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR | MAP3K20, SBK3, MAPKAPK2 | AGTR1 2449/4885NPC1 2720/4885RAB9A 1320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.